Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| EXEL | EXELIXIS, INC. | 2025-10-30 18:27:41 | 39.23 | 0.29 | 0.74 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | 0000939767 | EXELIXIS, INC. | US30161Q1040 | 254900PJQB59O2O95R37 | 043257395 | Nasdaq | 2836 | Biological Products, (No Diagnostic Substances) | 0102 | DE | 1851 HARBOR BAY PARKWAY | ALAMEDA | CA | 94502 | UNITED STATES | US | 6508377000 | 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502 | 1851 HARBOR BAY PARKWAY, ALAMEDA, CA, 94502 | EXELIXIS INC | Biotechnology | 1994 | Michael M. Morrissey, Ph.D. | 954 | http://exelixis.com | 4,800,000,000 | 270,132,000 | 269,202,521 | Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. | 2025-10-30 12:54:29 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 4,800,000,000 | 100,000,000 | 2.1277 | 279,881,450 | -23,312,809 | -7.6891 |
| 2023 | 4,700,000,000 | -2,131,299,691 | -31.199 | 303,194,259 | -20,893,078 | -6.4467 |
| 2022 | 6,831,299,691 | 1,151,233,827 | 20.268 | 324,087,337 | 4,639,163 | 1.4522 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Jeffrey J. Hessekiel, J.D. | Executive Vice President, General Counsel | 2024 | 685,882 | 0 | 2,624,591 | 415,243 | 11,000 | 3,736,716 |
| Christopher J. Senner | Chief Financial Officer, Executive Vice President | 2024 | 788,288 | 0 | 3,402,273 | 478,599 | 11,000 | 4,680,160 |
| Michael M. Morrissey | Chief Executive Officer, President | 2024 | 1,252,636 | 0 | 10,012,388 | 1,456,024 | 11,000 | 12,732,048 |
| Dana T. Aftab, Ph.D. | Chief Scientific Officer, Executive Vice President | 2024 | 619,316 | 0 | 2,624,591 | 361,671 | 11,000 | 3,616,578 |
| Amy C. Peterson, M.D. | Chief Medical Officer, Executive Vice President | 2024 | 654,337 | 0 | 3,402,273 | 378,405 | 11,000 | 4,446,015 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 1,147 |
| 2023 | 1,310 |
| 2022 | 1,223 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 2,168,701,000 | 1,830,208,000 | 1,611,062,000 |
| Cost Of Revenue | 76,216,000 | 72,547,000 | 57,909,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 910,408,000 | 1,044,071,000 | 891,813,000 |
| General And Administrative Expenses | 492,128,000 | 542,705,000 | 459,856,000 |
| Operating Expenses | 1,564,084,000 | 1,659,323,000 | 1,409,578,000 |
| Operating Income | 604,617,000 | 170,885,000 | 201,484,000 |
| Net Income | 521,267,000 | 207,765,000 | 182,282,000 |
| Earnings Per Share Basic | 1.8 | 0.65 | 0.57 |
| Earnings Per Share Diluted | 1.76 | 0.65 | 0.56 |
| Weighted Average Shares Outstanding Basic | 290,030,000 | 318,151,000 | 321,526,000 |
| Weighted Average Shares Outstanding Diluted | 296,132,000 | 321,464,000 | 324,556,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 217,374,000 | 262,994,000 | 501,195,000 |
| Marketable Securities Current | 893,902,000 | 732,308,000 | 807,273,000 |
| Accounts Receivable | 265,437,000 | 237,407,000 | 214,784,000 |
| Inventories | 22,388,000 | 17,323,000 | 33,299,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 1,467,579,000 | 1,317,958,000 | 1,618,762,000 |
| Marketable Securities Non Current | 637,291,000 | 728,717,000 | 756,731,000 |
| Property Plant And Equipment | 119,391,000 | 128,731,000 | 110,624,000 |
| Other Assets Non Current | — | — | — |
| Total Assets Non Current | 1,480,111,000 | 1,624,399,000 | 1,452,727,000 |
| Total Assets | 2,947,690,000 | 2,942,357,000 | 3,071,489,000 |
| Accounts Payable | 38,191,000 | 33,768,000 | 32,667,000 |
| Deferred Revenue | 2,739,000 | 5,406,000 | 7,488,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 95,012,000 | 108,417,000 | 78,924,000 |
| Total Liabilities Current | 403,769,000 | 394,277,000 | 324,359,000 |
| Long Term Debt | — | — | — |
| Other Liabilities Non Current | 108,895,000 | 94,224,000 | 61,951,000 |
| Total Liabilities Non Current | 299,718,000 | 284,168,000 | 258,703,000 |
| Total Liabilities | 703,487,000 | 678,445,000 | 583,062,000 |
| Common Stock | 282,000 | 303,000 | 324,000 |
| Retained Earnings | -98,647,000 | -173,351,000 | -34,225,000 |
| Accumulated Other Comprehensive Income | -1,347,000 | -3,750,000 | -14,521,000 |
| Total Shareholders Equity | 2,244,203,000 | 2,263,912,000 | 2,488,427,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 28,803,000 | 25,717,000 | 20,875,000 |
| Share Based Compensation Expense | 93,836,000 | 106,345,000 | 107,574,000 |
| Other Non Cash Income Expense | 13,626,000 | 16,797,000 | 525,000 |
| Change In Accounts Receivable | 27,950,000 | 22,623,000 | -66,849,000 |
| Change In Inventories | -5,453,000 | 12,977,000 | 11,683,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -21,886,000 | 53,246,000 | 25,842,000 |
| Change In Other Liabilities | -149,000 | 1,345,000 | -63,065,000 |
| Cash From Operating Activities | 699,971,000 | 333,324,000 | 362,614,000 |
| Purchases Of Marketable Securities | 927,905,000 | 902,468,000 | 1,450,716,000 |
| Sales Of Marketable Securities | 877,307,000 | 1,038,482,000 | 1,064,758,000 |
| Acquisition Of Property Plant And Equipment | 28,435,000 | 40,469,000 | 27,706,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -116,783,000 | -26,955,000 | -524,414,000 |
| Tax Withholding For Share Based Compensation | 38,625,000 | 29,122,000 | 23,300,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 12,100,000 | 12,700,000 | 10,100,000 |
| Repurchase Of Common Stock | 661,229,000 | 554,870,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 61,850,000 | 33,448,000 | 23,886,000 |
| Cash From Financing Activities | -628,808,000 | -546,052,000 | 586,000 |
| Change In Cash | -45,620,000 | -239,683,000 | -161,214,000 |
| Cash At End Of Period | 217,374,000 | 262,994,000 | 501,195,000 |
| Income Taxes Paid | 170,482,000 | 185,658,000 | 127,870,000 |
| Interest Paid | — | — | — |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 1.8 | 0.65 | 0.57 |
| Price To Earnings Ratio | 18.8722 | 36.9077 | 28.1404 |
| Earnings Growth Rate | 176.9231 | 14.0351 | -21.9178 |
| Price Earnings To Growth Ratio | 0.1067 | 2.6297 | -1.2839 |
| Book Value Per Share | 7.7378 | 7.1158 | 7.7394 |
| Price To Book Ratio | 4.3901 | 3.3714 | 2.0725 |
| Ebitda | 720,552,000 | 419,140,000 | 331,027,000 |
| Enterprise Value | — | — | — |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | — |
| Capital Expenditures | 19,463,000 | 43,824,000 | 27,468,000 |
| Free Cash Flow | 680,508,000 | 289,500,000 | 335,146,000 |
| Return On Equity | 0.2323 | 0.0918 | 0.0733 |
| One Year Beta | 0.2002 | 0.3988 | 0.7562 |
| Three Year Beta | 0.586 | 0.6831 | 0.799 |
| Five Year Beta | 0.724 | 0.8069 | 0.9169 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Aftab Dana | EVP, Research & Development | 2025-10-08 | 50,673 | A | 713,161 |
| WYSZOMIERSKI JACK L | Director | 2025-06-03 | 7,535 | D | 358,882 |
| Eckhardt Sue Gail | Director | 2025-06-02 | 18,834 | D | 21,384 |
| Eckhardt Sue Gail | Director | 2025-06-02 | 4 | D | 21,380 |
| Smith Julie | Director | 2025-05-29 | 9,812 | A | 20,590 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 2,626,598 | 63,598 | 41.3 |
| GRANDFIELD & DODD, LLC | 2025-09-30 | 1,115,141 | 27,001 | 41.3 |
| MOKAN Wealth Management Inc. | 2025-09-30 | 205,644 | 4,981 | 41.2857 |
| Parkside Financial Bank & Trust | 2025-09-30 | 39,566 | 958 | 41.3006 |
| Arcus Capital Partners, LLC | 2025-09-30 | 290,009 | 7,022 | 41.3001 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SHELTON FUNDS | 2025-08-31 | K Shares | MIDKX | 9,672 | 361,926.24 | 0.3348 |
| SHELTON FUNDS | 2025-08-31 | Investor Shares | SPMIX | 9,672 | 361,926.24 | 0.3348 |
| Global X Funds | 2025-08-31 | Global X U.S. Cash Flow Kings 100 ETF | FLOW | 3,569 | 133,551.98 | 0.5552 |
| Global X Funds | 2025-08-31 | Global X Aging Population ETF | AGNG | 13,600 | 508,912 | 0.7894 |
| ETF Series Solutions | 2025-08-31 | Vident U.S. Equity Strategy ETF | VUSE | 110,446 | 4,132,889.32 | 0.5874 |